© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Tina Q. Tan, MD
Articles
Practice Pearls for Discussing COVID-19 Vaccines with Patients
January 12, 2024
Drs Tina Q. Tan and Rodney Rohde share final thoughts on addressing patient and parent concerns with COVID-19 vaccines.
mRNA Technology in COVID-19 Vaccine Production
January 12, 2024
Experts comment on the significance of mRNA (messenger RNA) technology in developing COVID-19 vaccines, as well as vaccines against other viral infections.
Approaching Patient Education About COVID-19 Vaccination
January 12, 2024
Rodney Rohde, PhD, MS, SM(ASCP)CM, shares his approach to initiating conversations around COVID-19 vaccination to patients and family members, highlighting the safety of administering multiple vaccines at during 1 visit.
Dosing Strategy and Final Pearls for Nirsevimab for RSV
September 18, 2023
Experts conclude their discussion on the efficacy and safety study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on possible dosing strategies and key takeaways from this study.
Adverse Events Observed in Study of Nirsevimab for RSV
September 18, 2023
Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.
Infant Weight and Efficacy Outcomes of Nirsevimab for RSV
September 18, 2023
Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.
RSV Strains and Nirsevimab for RSV
September 18, 2023
Experts discuss data relating to the strains of Respiratory Syncytial Virus (RSV) and how clinicians should consider them in relation to the efficacy of nirsevimab.
Time-To-Event Analysis and Discussion on the Efficacy Nirsevimab for RSV
September 18, 2023
Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.
Data Review of Efficacy and Safety Study of Nirsevimab for RSV
September 18, 2023
Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, discuss the initial efficacy data of the study on nirsevimab for Respiratory Syncytial Virus (RSV) and how it compared to placebo.
Discussion of Study Patient Population on Nirsevimab for RSV
September 18, 2023
Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the patient population of the safety and efficacy study on nirsevimab for Respiratory Syncytial Virus (RSV).